Adalimumab biosimilar (Fujifilm Kyowa Kirin Biologics/Mylan)

阿达木单抗生物类似药（富士-协和麒麟生物制剂公司/迈兰制药）

Report date: 2026/03/26 20:00:17

Base Information

Drug NameAdalimumab biosimilar (Fujifilm Kyowa Kirin Biologics/Mylan)
Drug Alias NameRecombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Fujifilm Kyowa Kirin Biologics/Mylan)阿达木单抗生物仿制药（富士-协和麒麟生物制剂公司/迈兰制药）重组抗肿瘤坏死因子-α全人源单抗（富士-协和麒麟生物制剂公司/迈兰制药）重组抗TNFa全人单抗（富士-协和麒麟生物制剂公司/迈兰制药）Hulio +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor α inhibitorsImmunosuppressants
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitisBehcet Syndrome +[10] 
Global Approved IndicationsPsoriasisUveitisBehcet Syndrome +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/09/16
Country/TerritoryCzechiaBulgariaCanada +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFujifilm Kyowa Kirin Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiosimilar Collaborations Ireland LtdFujifilm Kyowa Kirin Biologics Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisUveitisBehcet Syndrome +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A